Temozolomide and Radiotherapy for Newly Diagnosed Glioblastoma Multiforme: A Systematic Review

被引：50
作者：
Yang, Li-Juan [1 ]
Zhou, Chang-Fu [2 ]
Lin, Zhi-Xiong [2 ]
机构：
[1] Fujian Med Univ, Dept Pharmacol, Fuzhou 350005, Fujian, Peoples R China
[2] Fujian Med Univ, Affiliated Hosp 1, Dept Neurosurg, Fuzhou 350005, Fujian, Peoples R China
来源：
CANCER INVESTIGATION | 2014年 / 32卷 / 02期
关键词：
Efficacy; Glioblastoma multiforme; Radiotherapy; Review; Systematic; Safety; Temozolomide; ADJUVANT CHEMOTHERAPY; RADIATION-THERAPY; PHASE-II; CONCOMITANT; BEVACIZUMAB; GLIOMAS; TRIAL;
D O I：
10.3109/07357907.2013.861474
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
To systematically review the efficacy/safety of radiotherapy/temozolomide (TMZ) vs. radiotherapy for treating glioblastoma (GBM), Medline, Current Contents, and Cochrane database were searched. Five studies were reviewed. Median survival ranged from 9.4 to 19.0 months (radiotherapy/TMZ) vs. 7.3-17.1 months (radiotherapy). Survival ranged from 80.2% to 95.0% (radiotherapy/TMZ) vs. 8.3-84.2% (radiotherapy) at 0.5 years and from 20.0% to 61.1% (radiotherapy/TMZ) vs. 5.0-50.6% (radiotherapy) at 1 year. Median progression-free survival (PFS) ranged from 5.5 to 13.0 months (radiotherapy/TMZ) vs. 4.4-7.6 months (radiotherapy). PFS rates at 0.5 years ranged from 53.9-78.0% (radiotherapy/TMZ) vs. 53.9-78.0% (radiotherapy). Radiotherapy/TMZ provides better survival outcomes than radiotherapy alone in treating GBM.
引用
收藏
页码：31 / 36
页数：6
相关论文
共 20 条
[1]   Glioblastoma multiforme: a review of where we have been and where we are going [J].
Adamson, Cory ;
Kanu, Okezie O. ;
Mehta, Ankit I. ;
Di, Chunhui ;
Lin, Ningjing ;
Mattox, Austin K. ;
Bigner, Darell D. .
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2009, 18 (08) :1061-1083
[2]   Glioblastoma Multiforme Overview of Current Treatment and Future Perspectives [J].
Anton, Kevin ;
Baehring, Joachim M. ;
Mayer, Tina .
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2012, 26 (04) :825-+
[3]   Randomized phase II study of temozolomide and radiotherapy compared with radiotherapy alone in newly diagnosed glioblastoma multiforme [J].
Athanassiou, H ;
Synodinou, M ;
Maragoudakis, E ;
Paraskevaidis, M ;
Verigos, C ;
Misailidou, D ;
Antonadou, D ;
Saris, G ;
Beroukas, K ;
Karageorgis, P .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (10) :2372-2377
[4]   Food and Drug Administration drug approval summary: Temozolomide plus radiation therapy for the treatment of newly diagnosed glioblastoma multiforme [J].
Cohen, MH ;
Johnson, JR ;
Pazdur, R .
CLINICAL CANCER RESEARCH, 2005, 11 (19) :6767-6771
[5]   Temozolomide for high grade glioma [J].
Hart, Michael G. ;
Garside, Ruth ;
Rogers, Gabriel ;
Stein, Ken ;
Grant, Robin .
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2013, (04)
[6]   Hypofractionated radiotherapy for glioblastoma: strategy for poor-risk patients or hope for the future? [J].
Hingorani, M. ;
Colley, W. P. ;
Dixit, S. ;
Beavis, A. M. .
BRITISH JOURNAL OF RADIOLOGY, 2012, 85 (1017) :E770-E781
[7]  
Karacetin D, 2011, J BUON, V16, P133
[8]   Randomized Study of Postoperative Radiotherapy and Simultaneous Temozolomide without Adjuvant Chemotherapy for Glioblastoma [J].
Kocher, Martin ;
Frommolt, Peter ;
Borberg, Sigrid Klara ;
Ruehl, Ursula ;
Steingraeber, Maria ;
Niewald, Markus ;
Staar, Susanne ;
Stuschke, Martin ;
Becker, Gerd ;
Fischedick, Arnt-Rene ;
Herfarth, Klaus ;
Grauthoff, Hermann ;
Mueller, Rolf-Peter .
STRAHLENTHERAPIE UND ONKOLOGIE, 2008, 184 (11) :572-579
[9]   Short-term radiotherapy followed by adjuvant chemotherapy in poor-prognosis patients with glioblastoma [J].
Muni, Roberta ;
Minniti, Giuseppe ;
Lanzetta, Gaetano ;
Caporello, Paola ;
Frati, Alessandro ;
Enrici, Maurizio Maurizi ;
Marchetti, Paolo ;
Enrici, Riccardo Maurizi .
TUMORI JOURNAL, 2010, 96 (01) :60-64
[10]   Temozolomide and Other Potential Agents for the Treatment of Glioblastoma Multiforme [J].
Nagasawa, Daniel T. ;
Chow, Frances ;
Yew, Andrew ;
Kim, Won ;
Cremer, Nicole ;
Yang, Isaac .
NEUROSURGERY CLINICS OF NORTH AMERICA, 2012, 23 (02) :307-+
12